Skip to main content

News

PENTHROX® RECEIVES MARKETING AUTHORIZATION FROM HEALTH CANADA FOR ADULT PATIENTS REQUIRING RELIEF FROM MODERATE TO SEVERE ACUTE PAIN ASSOCIATED WITH TRAUMA OR INTERVENTIONAL MEDICAL PROCEDURES

Published on April 10, 2018

Pickering, ON (Canada) (April 10, 2018): Purdue Pharma (Canada) and Medical Developments International Limited (MDI),…

Read More

NEW TREATMENT OPTION FOR ADULTS WITH ADHD: FOQUEST™ (METHYLPHENIDATE CONTROLLED RELEASE CAPSULES) NOW AVAILABLE IN CANADA

Published on February 1, 2018

First and only methylphenidate product approved in Canada with a 16-hour duration of action PICKERING,…

Read More

BELBUCA® – A NEW TREATMENT OPTION FOR CANADIANS LIVING WITH CHRONIC PAIN – NOW AVAILABLE IN CANADA

Published on January 30, 2018

Pickering, ON (Canada) (January 30, 2018): Purdue Pharma (Canada) and BioDelivery Sciences International Inc. (BDSI)…

Read More

NEW SINGLE CAPSULE TREATMENT AKYNZEO™ NOW AVAILABLE FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN CANADA

Published on November 28, 2017

Pickering, ON (Canada) (November 28, 2017): Purdue Pharma (Canada) announce today that AKYNZEO™ (netupitant/palonosetron hydrochloride)…

Read More

ARCHIVE

2018
2017
2016
2015
2014
2013
2012

For all media inquiries, please contact:

media@purdue.ca

↓